Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy M Shefner

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
Muscle & Nerve|May 24, 2020
Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunitiesJinsy A Andrews, James D Berry, Robert H Baloh, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|June 8, 2012
Electrical impedance myography as a biomarker to assess ALS progressionSeward B Rutkove, James B Caress, Michael S Cartwright, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 28, 2013
Designing clinical trials for dystoniaWendy R Galpern, Christopher S Coffey, Alberto Albanese, et al.
Neurology|April 26, 2019
Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studiesBasil T Darras, Claudia A Chiriboga, Susan T Iannaccone, et al.
Plos One|April 25, 2013
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosisJames D Berry, Jeremy M Shefner, Robin Conwit, et al.
Neurology|February 26, 2016
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progressionMichael D Weiss, Eric A Macklin, Zachary Simmons, et al.
The Lancet. Neurology|October 10, 2014
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trialMerit E Cudkowicz, Sarah Titus, Marianne Kearney, et al.
The Lancet. Neurology|February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialVincent Meininger, Angela Genge, Leonard H van den Berg, et al.
Science Translational Medicine|December 21, 2012
Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysisYang D Teng, Susanna C Benn, Steven N Kalkanis, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 11, 2020
A proposal for new diagnostic criteria for ALSJeremy M Shefner, Ammar Al-Chalabi, Mark R Baker, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
Muscle & Nerve|May 24, 2020
Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunitiesJinsy A Andrews, James D Berry, Robert H Baloh, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|June 8, 2012
Electrical impedance myography as a biomarker to assess ALS progressionSeward B Rutkove, James B Caress, Michael S Cartwright, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 28, 2013
Designing clinical trials for dystoniaWendy R Galpern, Christopher S Coffey, Alberto Albanese, et al.
Neurology|April 26, 2019
Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studiesBasil T Darras, Claudia A Chiriboga, Susan T Iannaccone, et al.
Plos One|April 25, 2013
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosisJames D Berry, Jeremy M Shefner, Robin Conwit, et al.
Neurology|February 26, 2016
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progressionMichael D Weiss, Eric A Macklin, Zachary Simmons, et al.
The Lancet. Neurology|October 10, 2014
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trialMerit E Cudkowicz, Sarah Titus, Marianne Kearney, et al.
The Lancet. Neurology|February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialVincent Meininger, Angela Genge, Leonard H van den Berg, et al.
Science Translational Medicine|December 21, 2012
Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysisYang D Teng, Susanna C Benn, Steven N Kalkanis, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 11, 2020
A proposal for new diagnostic criteria for ALSJeremy M Shefner, Ammar Al-Chalabi, Mark R Baker, et al.
Pageof 11